Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Enzalutamide and Decitabine in mCRPC
NCT03709550Phase 2Withdrawn
- Sponsor
- Roswell Park Comprehensive Cancer Center
- Start
- Apr 2021
- Primary completion
- Apr 2023
- Countries
- 1
01
Overview
A Phase 2 trial of decitabine in metastatic castration-resistant prostate cancer (mCRPC), sponsored by Roswell Park Comprehensive Cancer Center. Planned start Apr 2021; status: withdrawn.
02
Drugs
decitabine
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT03709550.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03709550.